key: cord-0692798-xp20flhc
authors: Verma, Surjeet; Patel, Chirag N.; Chandra, Muktesh
title: Identification of novel inhibitors of SARS‐CoV‐2 main protease (M(pro)) from Withania sp. by molecular docking and molecular dynamics simulation
date: 2021-07-20
journal: J Comput Chem
DOI: 10.1002/jcc.26717
sha: a1e6cd405bd92df71504a1fbd72fc13d41a622de
doc_id: 692798
cord_uid: xp20flhc

Since December 2019, coronavirus disease (COVID‐19) has claimed the lives of millions of people across the globe. To date, no medicine is available for the responsible virus SARS‐CoV‐2. 3CLpro, that is, 3‐chymotrypsin‐like protease, the main protease (M(pro)), has an important role in cleaving pp1a and pp1ab polyproteins. This M(pro) serves as an important target in drug designing against COVID‐19. Herein, the study includes the investigation, screening, and identification of potent leads from (Withania sps.), against SARS‐CoV‐2, using virtual screening, molecular docking, and molecular dynamics (MD) simulations. Seventy‐three natural compounds from this important medicinal plant were screened. The Binding affinity was used to identify the most probable target to inhibit the M(pro), compounds 27‐hydroxywithanolide F (W32, −11.5 kcal/mol), withanolide A (W56, −11.4 kcal/mol), and withacoagulin H (W30, −11.1 kcal/mol) showed highest binding energy. Lipinski's rule, followed by drug‐likability and likeness screening, resulted in 36 molecules. Further, MD simulation of 50 ns predicted withacoagulin H possessing strong binding affinity and hydrogen‐bonding interactions with the active site. The binding free energy calculation showed the most negative energy of withacoagulin H (−63.463 KJ/mol) compared to other selected compounds. The study also compared the bonding energy of already reported repurposed and newly synthesized drugs. Further, absorption, distribution, metabolism, and excretion predictions were made to found a good balance of potency. Hence the following screened compounds from Withania sps. could serve as the potential leads for drug development against COVID‐19.

The first case for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in the live wildlife market at Hubei province of China in December 2019. 1 Since its inception, the virus has made unprecedented growth and affected the human population worldwide. Due to the increased number of cases worldwide, the World Health Organization declared it a pandemic on March 11, 2020. The novel SARS-CoV-2 infection creates a pneumonia-like condition known as COVID- 19 . Symptoms such as sore throat, fever, and dry cough are observed, causing complications like septic, pulmonary edema, organ failure, and Acute Respiratory Distress Syndrome. 2 In such a devastating situation development of medication are much needed.

There are four classes of coronaviruses, namely alpha, beta, gamma, and delta. SARS and Middle East respiratory syndrome (MERS) belongs to the beta category. The causative agent for COVID-19 is SARS-CoV2. 3 The virus got SARS-CoV-2, the name due to the 82% similarity of its RNA genome with SARS-CoV. The SARS-CoV-2 consists of a 30 kb long single-stranded RNA molecule with a 5 0 cap and 3 0 poly-A tail with positive polarity. Its virion consists of crownshaped peplomers, with 80-160 nm in diameter. 4 The CoVs consist of four structural proteins, namely spike (S protein), envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein. The N protein participates in RNA genome packaging, and S, M, E proteins are involved in forming a viral coat. 5 The COVID-19 genome, for its replication and transcription, encodes two replicase proteins, pp1a and pp1ab. 6 The main protease (M pro ) releases the functional peptides from the polyproteins through extensive proteolytic processing. M pro is vital for the viral life cycle as it digests the polyproteins at 11 conserved sites by autolytic cleavage by pp1a and pp1ab. 7 Moreover, the absence of homologs in humans makes it a perfect target for antiviral drug design.

As per the information, SARS-CoV-2 has a low fatality rate but In recent years, strategies such as drug repurposing have played a crucial role in speeding the drug designing against rapidly spreading infections, either be Ebola infection, Hepatitis C, Zika virus, or the SARS-CoV-2. [8] [9] [10] Repurposing investigations revealed various medications, such as lopinavir, remdesivir, lopinavir-ritonavir, hydroxychloroquine, ivermectin, and numerous other natural products and natural product-derived compounds, had good effectiveness against SARS-CoV-2. 11, 12 Moreover, few other repurposed synthetic molecules have shown good inhibitory activity against SARS-CoV-2 M pro in-vitro. 6, 13 Several molecules isolated from various plants such as Glycyrrhiza glabra, Asparagus rasemosus, Ocimum basilicum, Ocimum sanctum, Clonorchis sinensis, and Withania somnifera, and so forth, also exhibit antiviral properties. [14] [15] [16] Recently, few phyto-molecules including oolonghomobisflavan-A, theasinensin-D, theaflavin-3-O-gallate, glycyrrhizic acid, asparoside-C, D, and F have been identified as potential inhibitors of SARS-CoV-2 M pro and spike protein in several in-silico studies. [17] [18] [19] The glycyrrhizic acid, its derivatives, and other triterpenes have shown great inhibition potential against SARS-CoV replication and cytopathic effect in-vitro. Due to the 82% of RNA genome similarity between SARS-CoV and SARS-CoV-2, Verma et al. 11 have hypothesized that these compounds or similar compounds may potentially inhibit SARS-CoV-2 viral replication and infection as well. Furthermore, few similar steroidal glycosides such as abiraterone acetate, ouabain, digoxin, and digitoxin have shown promising in-vitro inhibitory activity against SARS-CoV-2. 12 Following this hypothesis having the close structural similarity to these compounds, 73 withanolides isolated from five Withania species were selected from the literature and screened virtually. Further, the rule of five analyses reduced the list of molecules. In-silico studies, including molecular docking simulation, were done to screen the potential inhibitors for M pro of SARS-CoV-2. Absorption, distribution, metabolism, and excretion (ADME) prediction provided the bioavailability score (ABS) and permeability of molecules which act as an essential factor for drug designing. Furthermore, we envisage that in-vitro and in-vivo studies should be conducted for better inhibitory potential on these selected molecules, serving as a template for drug design for M pro from SARS-CoV-2.

The three-dimensional structure of SARS-CoV-2 M pro , PDB ID 6Y2F, with a resolution of 1.95, was retrieved from the protein data bank. 3 The structure of reference compounds (RC1-5) and 73 Withania compounds (W1-73) were collected from the literature. 6, 11, 20 The local database of names and structures of all the compounds (Table S1 ) was created by drawing their structure through ChemDraw ultra12 and saved in SDF format. These 2D formats of molecules were transformed to the 3D coordinates and optimized using the GUI version of Openbabel2.3.2. 21 

The crystal structure was prepared for binding analysis using Autodock Tools (ADT). 22 Protein preparation included adding charges (Gasteiger charges), polar hydrogens, and optimizing the rotatable bonds. Prepared protein was thus saved in pdbqt format for further analysis. The idea of a binding site was obtained from already available information the coordinates around the centre atom of the active site considered for the generation of the grid box. ADT received the information of the grid box based on the above information. The grid box for PDB ID 6Y2F considered was with coordinates as 10.601, À0.613, and 21.174 for x, y, and z-axis, respectively. The size of the grid box was manually adjusted and set as 20.180 Â 20.180 Â 20.180. The configuration file was created using the receptor, ligand, and grid parameters information before the final execution of the molecular docking. In the virtual screening process, already reported drug molecules, lopinavir, and RC1-4 were used as control molecules throughout the study.

All the biomolecules and the control molecules were prepared using ADT by adding polar hydrogen and gasteiger charges. After adjusting the rotatable bonds and torsion angle, each of the molecules was saved in pdbqt format. The molecular docking output files were analyzed based on ligand and protein binding energy and interactions profile. The protein-ligand interaction profile was utilized to evaluate the interactions.

Lipinski's rule of five was considered the primary factor for screening the molecules. 23 After screening, the molecules were subjected to ADME risk assessment software to ascertain their risk for drugability. Physiochemical properties were evaluated to understand the oral activity of molecules through Lipinski's rules.

Most drugs fail in the discovery process in reaching clinical trials, which happens due to poor pharmacokinetics (PK). The PK properties were calculated for drug testing toward ADME. 24 The study included physiochemical properties estimation (such as molecular weight For this bond orders assignments, the addition of hydrogens, and filling of missing amino acid chain and loops, and hydrogen bond assignment optimization. System Builder module applied to build the periodic simulation box and single point charge water model used for salvation, with Optimized Potentials for Liquid Simulations (OPLS) allatom force field. The system was minimized using the steepest descent technique for 1000 iterations. After equilibration, the unrestrained production phase ran under NPT (number of atoms, pressure, and temperature were kept constant) ensemble for 50 ns at 300 K temperature and 1.01325 bar pressure. Nosé-Hoover thermostat (relaxation time = 1 ps) and the isotropic Martyna-Tobias-Klein barostat (relaxation time = 2 ps) were applied. Short-range interactions (cutoff = 9 Å) and long-range Coulombic interactions were evaluated using the smooth particle mesh Ewald (PME) method with the RESPA integrator. The conformations captured in the simulation trajectories were exported at every 5 ps. After completing simulations, the system's stability was assessed using root mean square deviation (RMSD), root mean square fluctuations (RMSF), Hydrogen bond analysis, the radius of gyration (rGyr), and the histogram for torsional bonds.

To ascertain the binding free energy of protein-ligand complex calculations are made based on Molecular mechanics generalized Born surface area (MM/GBSA). A total 50 ns trajectory was submitted to the prime module of Schrödinger to perform MM/GBSA calculations. 26 Estimations of free energy are based on the following equation

where, ΔG is free energy for the respective complex, receptor, and ligand. 

In the current scenario, virtual screening of phytochemicals plays an important part in the drug discovery process. Virtual screening performed based on pharmaco-informatics approach utilizing in-silico tools plays a pivotal role in discovering drug against the pathogen. 27 M pro of SARS-CoV-2 is a dimeric cysteine protease, with two promoters oriented at right angles to each other. 28 SARS M pro active site is similar to that of human CoV (HCoV) and porcine transmissible gastroenteritis virus, consisting of a Cys-His dyad with positional variations. 28 Coronavirus utilizes chymotrypsin-like protease and papain protease to cleave long polyprotein precursors into individual functional Nsps, essential for virus life. 5 Hence, M pro becomes the main target for anti-coronavirus drug development. A set of 73 molecules were docked to the binding site of M pro , and prioritization was made based on interaction energy scores. Molecule W48 (À13.0 kcal/mol), W32 (À11.5 kcal/mol), W56 (À11.4 kcal/mol), W30 (À11.1 kcal/mol), W60 (À11.0 kcal/mol), W52 (À10.9 kcal/mol), W34 (À10.8 kcal/mol), and W55 (À10.6 kcal/mol) binding affinity (Table 1 and Table S1) were more than that of RC1 (À5.8 kcal/mol), RC2 (À6.9 kcal/mol), RC3 (À7.7 kcal/mol), RC4 (À8.3 kcal/mol), and RC5 (À7.1 kcal/mol).

The other molecules also showed good binding scores as defined (Table S1 ). The discovery studio visualizer examined the interacting residues between the active site and selected molecules. Re-docking of the initial inhibitor was conducted with SARS-CoV-2 M pro and found 0.00 Å RMSD between the docked pose and crystal structure available RCSB database. 

Drug discovery requires passing out drug candidate molecules in subsequent preclinical, clinical, and further commercial phases of drug development. The development of automated and improved in-silico methods had increased the ability to dissect the fundamentals of ADME/PK. Undesirable and dispossessed pharmacokinetic properties become the primary reason for the compound to phase out from the process of drug discovery. Lipinski's rule was used to filter the compounds and assess the chemical properties related to oral bioavailability. Out of 73 natural biomolecules from Withania, only 36 could make it through the rule of five with zero violations (Table 2) . These 36 compounds were further evaluated for pharmacokinetics compliance, including ADME. To avoid failure at later stages of drug development, compliance with pharmacokinetic parameters are of utmost importance. Despite having a high binding affinity, compounds W48, W51, W52, W54, W60, and W61 did not pass the rule of five and hence were not included in further testing.

In-silico inhibition constant (Ki) expresses the inhibitor concentration required to inhibit the chemical reaction 50% at a specific substrate concentration. 31 Ki value of the top nine molecules and reference compounds were predicted as per docking score ( (Figure 1   (A,B,D,G,H) and Table 3 ). Similarly, H-bond, Pi-alkyl bonds, and VdW by W62, W33, W36, and W39 (Figure 1(C,E,I) and Table 3 ). The in-vitro tested molecules were also analyzed for binding residues, and they also showed binding with the HisCys dyad. In RC5, the three H- interactions were also manifested ( Figure 2 and Table 3 ). Hydrogen bonds are intermolecular interactions, play an important role in determining molecular aggregations and conformations. Their presence becomes an important factor in governing the dynamics and functions. 32 Binding interactions such as H-bond, carbon-hydrogen bonds, π-alkyl, alkyl, Pi-sigma, Van der Waals, and so forth interactions play an important role in the binding of the molecule to the substrate.

Further, drug-like physicochemical properties were calculated by

Lipinski's rule of five for the candidate compounds. Drug likeness is an essential consideration in the early phases of drug discovery for compound selection with desired bioavailability. 33 Approaches such as a quantitative estimate of drug-likeness, 32 oral PhysChem score, 33 ABS, 34 or Gaussian scoring function 35 include physiochemical parameters into the drug-likeness score, assisting in compound screening.

Physiochemical properties such as permeability, lipophilicity, solubility, affinity, and metabolic stability were also assessed. Screened compounds ABS was 0.55, which signifies that the compounds passed

Lipinski's rule of five. 23 ADME and molecular PK were also taken into consideration. Such as solubility with water, absorption by the intestine, hepatotoxicity, plasma protein binding, GI absorption, bloodbrain penetration (BBB), and interaction with cytochrome P450 (CYP).

Rules define, though, cannot predict the pharmacological activity of compounds. Yet, these rules in a well-defined stepwise manner play a crucial role in determining the significant lead molecules for protein specificity and biological activity. To adjudicate the significance of compounds, MW is considered the essential factor, that is, MW of the compound should be between 150 and 500 g/mol ( Table 2) .

Lipophilicity is signified as the coefficient between n-octanol and water (log P o/w ), that is, the ratio of solubility of the compound in octanol compared to its solubility in an aqueous medium. MW in collaboration with log P defined as an important factor for permeability.

Similarly, water solubility determined by log S value which did not exceeded six for compound to be soluble. log S along with determinants such as MW, number of rotatable bonds, fraction of aromatic heavy atoms and log P, defines the compounds are soluble in aqueous medium ( Table 4 ).

The candidate compounds have high bioavailability because they do not violate Lipinski's rule of five, that is, their molecular mass is below 500 Da, they possess high lipophilicity (log P < 5), hydrogen donors (<5), hydrogen acceptors (<10), and, their molar refractivity lie F I G U R E 2 Interacting residues of reference compounds (2D format) with SARS-CoV-2 M pro (i) ebselen (RC1), (ii) tideglusib (RC2), (iii) GC373 (RC3), (iv) GC376 (RC4), (v) lopinavir (RC5)

T A B L E 4 Compliance of screened molecules with standard ranges of ADME and drug-likeness through the GI wall to lumen or from the brain. Additionally, CYP interactions were calculated to understand drug elimination through biotransformation. CYP interaction plays an important step in clearing a drug or its metabolite from the body leading to low/high toxicity.

The values of our probable compounds were within the range of standard drugs ( Table 4) . -19) . However, the in-vitro assessment is still to be done for the confirmation of the same. Apart from this, these plant species have been well known for their immune-boosting potential, 11 which is further advantageous in COVID-19 treatment.

Compounds The stability of the simulation system and protein backbone conformational perturbations due to simulation were measured using the RMSD value. 34 within the specified limits of RMSD (Figure 4(A) ). Further, RMSF analysis was performed to understand the docked complexes' residue-wise fluctuation. RMSF behavior was generated using the docked complexes; a plot was made using the RMSF, B factor, and interactions (Figure 4(B) ). Peaks indicate most protein fluctuations; it is understood that N-and C-terminal fluctuate more than any other part of the protein. Also, the secondary structure elements revealed that alpha helices and beta strands are rigid compared to the loops more fluctuated ( Figure S2 ). (Table 5) . Therefore, it can be stated that withacoagulin H with minimum binding energy and better binding affinity could prove to be a better inhibitor for M pro of SARS-CoV-2.

W30 becomes the compound of choice among all the screened compounds as it possesses an excellent binding affinity compared to other compounds. Interaction pattern shows its interaction with Hys41-Cys145 dyad, in simulation studies also its interaction with substrate binding region was maintained. In RMSD analysis, the fluctuations were within the acceptable range, making it a probable candidate.

Further, W30 showed the least binding energy on MM/GBSA analysis than W32 and W34. Hence, it becomes probable compound obtained from Withania to act as a likely inhibitor for the M pro of SARS-CoV-2.

In conclusion, 73 withanolides and selected reference compounds were screened based on Lipinski's rule of five. The binding affinity of these screened compounds in the active sites of M pro of SARS-CoV-2 was investigated further. Of these, nine molecules showed a significant docking score, even better than the reference compounds. ADME studies were also conducted for screened molecules to determine their drug-likeness and bioavailability. Since the molecules utilized here ADME was also determined, they can be the active lead for drug development of respective illness. The bioactive molecule from Withania showed good conformations with the M pro of SARS-CoV-2, stable complex was formed; these complexes showed a more significant number of hydrogen bonds and van der Waals interactions than the complexes with reference compounds. 

The authors declare that they have no conflict of interest that could influence the work reported in this article.

https://orcid.org/0000-0002-6154-0647

Evidence Based Validation of Traditional Medicines

ACM/IEEE Conference on Supercomputing

Drug Discovery Today 2020